Press Releases

Auris Medical Completes Enrollment of Phase 1b Proof-Of-Concept Trial of AM-201 in Antipsychotic-Induced Weight Gain

07/03/19

Auris Medical Holding Ltd Provides Corporate Update

05/23/19

Auris Medical Holding Ltd Regains Compliance with Nasdaq Minimum Bid Price Rule

05/20/19

Auris Medical Announces Closing of Public Offering of Common Shares

05/15/19

Auris Medical Announces Closing of Two US Patent Acquisitions Related to the Use of Betahistine for the Treatment of Depression and ADHD

05/15/19

Auris Medical Prices $8,000,000 Public Offering

05/13/19

Auris Medical Reaches Midpoint for Enrollment in AM-201 Phase 1b Proof-of-Concept Study in Antipsychotic-Induced Weight Gain

05/07/19

Auris Medical Announces Reverse Stock Split

04/30/19

Auris Medical Provides Update on Tinnitus Drug Development Strategy

04/25/19

Auris Medical Receives Positive Nasdaq Listing Determination

04/15/19

Auris Medical Announces Randomization of First Dose Cohort in AM-201 Phase 1b Proof-of-Concept Study

03/29/19

Auris Medical Announces 20-F Filing

03/14/19

Auris Medical Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results

03/14/19

Auris Medical Announces Publication of AM-111 Phase 3 Results in Peer-Reviewed Scientific Journal

03/11/19

Auris Medical to Report Fourth Quarter and Full Year 2018 Financial Results and Provide Business Update on Thursday, March 14, 2019

03/07/19

Auris Medical Announces Receipt of Nasdaq Notice

02/08/19

Auris Medical Announces Full Repayment of Hercules Loan Facility

02/01/19

Auris Medical to Redomicile Holding Company from Switzerland to Bermuda

01/29/19

Auris Medical Announces Publication of New Data Highlighting the Role of Betahistine in Promoting the Restoration of Forgotten Memories in Mice and Healthy Volunteers

01/23/19

Auris Medical Provides Update on Intranasal Betahistine Programs

01/15/19